komodo™

ALZHEIMER'S DISEASE

Up-to-date insights on disease, treatment, and care based on real-world data from Komodo's full-stack healthcare analytics platform

**Alzheimer's disease (AD) is a progressive neurological disorder and the seventh-leading cause of death in the United States.** While early detection and diagnosis can improve treatment options and quality of life for patients, many people are not diagnosed until the disease has progressed to a more severe stage. There has been an alarming increase in AD diagnoses among younger patient populations, and disparities based on race persist, putting certain communities at higher risk. Insights from Komodo's Healthcare Map™ highlight the need for increased awareness and access to care and support action from advocates, governments, and healthcare providers.

PREVALENCE

Based on data available in Komodo's Healthcare Map, there are approximately **5.12 million** insured Americans living with AD. That number jumps to

10 million when looking at both AD and related dementias.

Patients Living With Alzheimer's Disease & Related Dementia: Past 7 Years

DISPARITIES IN CARE

Emergency Room Visits Per Patient

Inpatient Admissions Per Patient

Compared with White patients with AD, patients of color with AD experienced*:

62% more healthcare encounters overall

47% more AD-specific encounters

20% more ER visits

54% more inpatient admissions

*Between Jan 2017 and June 2019

DIAGNOSIS AND MANAGEMENT

Most commonly performed diagnostic procedures one to six months before diagnosis:

- Blood test
- CT scan
- PET scan

These are most commonly performed one to six months before diagnosis.

Most frequently used therapies within two years after diagnosis:

- Memantine
- Rivastigmine
- Donepezil

Most frequently prescribed off-label schizophrenia medications:

- Quetiapine
- Olanzapine

DEMOGRAPHICS

Gender

Based on data available in Komodo's Healthcare Map, women were diagnosed with AD more often than men between 2020 to 2021.

Female **59.9%**

Male **40.1%**

Age

Between 2020 and 2021, diagnosis of early-onset AD increased by 18% (ages 45 to 65), while diagnosis in patients over age 89 decreased by 27%.

**0.90%**
25–44 Years Old

5.22%
45–64 Years Old

93.53%
65–88 Years Old

States With the Highest Prevalence

Florida (FL)

West Virginia (WV)

Maine (ME)

Connecticut (CT)

New York (NY)

Race and Ethnicity

White **73.3%**

Black **11.9%**

Hispanic or Latino **10.0%**

Asian or Pacific Islander **3.4%**

Other **1.4%**

MOST COMMON COMORBIDITIES

AD+

- Depression
- Anxiety
- Type 2 Diabetes
- Hypertension

TOP DIAGNOSING SPECIALTIES

1. **Internal Medicine**
2. **Family Practice**
3. **Nurse Practitioner**
4. **Neurology**
5. **Geriatric Medicine**